Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1

BACKGROUND: Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in transforming growth factor (TGF)-β1-induced IPF pathogenesis. However, unlike normal lung fibroblasts, the relatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jin, Togo, Shinsaku, Kadoya, Kotaro, Tulafu, Miniwan, Namba, Yukiko, Iwai, Moe, Watanabe, Junko, Nagahama, Kumi, Okabe, Takahiro, Hidayat, Moulid, Kodama, Yuzo, Kitamura, Hideya, Ogura, Takashi, Kitamura, Norikazu, Ikeo, Kazuho, Sasaki, Shinichi, Tominaga, Shigeru, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558902/
https://www.ncbi.nlm.nih.gov/pubmed/31185973
http://dx.doi.org/10.1186/s12931-019-1093-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558902/
https://www.ncbi.nlm.nih.gov/pubmed/31185973
http://dx.doi.org/10.1186/s12931-019-1093-z

Ejemplares similares